{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-039304","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.658730+00:00","generated_at":"2026-06-04T04:55:05.944011+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biomea Fusion reports Q4 2023 net loss $34.9M; cash $177.2M; clinical data readouts expected 2024","bullets":["Net loss $117.3M for FY 2023 vs $81.8M in 2022; Q4 loss $34.9M vs $25.3M.","Cash, equivalents, restricted cash, investments $177.2M at Dec 31, 2023, up from $113.4M year earlier.","R&D expenses $102.5M for FY 2023, up from $62.7M, driven by BMF-219 and BMF-500 clinical costs.","Phase 2 type 2 diabetes data showed continued glycemic control 5 months off therapy; expansion cohort of 216 patients underway.","Phase 2 type 1 diabetes study (COVALENT-112) initiated; initial data readout anticipated in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-039304","json":"https://secwatch.observer/filing/0000950170-24-039304.json","markdown":"https://secwatch.observer/filing/0000950170-24-039304.md","text":"https://secwatch.observer/filing/0000950170-24-039304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000095017024039304/0000950170-24-039304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000095017024039304/bmea-20240401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:55:05.944011+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dd55acd1b723fe00bc172b69ef94d1302df6bc69","claim":"Biomea Fusion, Inc. reported financial results for fourth quarter and full year 2023.","evidence_excerpt":"Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000095017024039304/0000950170-24-039304-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}